Eupraxia Pharmaceuticals
EPRX
7.52
-0.26
-3.34%
Eupraxia Pharmaceuticals
US · EPRX
#3732 by market cap
7.52
-0.26
-3.34%
Live - 5344 symbols - heartbeat 495s ago
· 2026-10-08 09:55
Pre-market
8.05
+3.47%
After-hours
7.78
0.00%
- Market cap
- 496.87M
- P/E (TTM)i
- -7.37
- P/Bi
- 4.88
- EPSi
- -1.03
- Div yieldi
- 0.00%
- 52W posi
- 56%
Reader sentiment
Are you bullish or bearish on EPRX?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 5.54M | 2.31M | 995.64K | 6.97M | 3.99M | 7.48M | 10.92M | 17.10M |
| Research & development | 4.88M | 2.25M | 674.25K | 7.59M | 13.63M | 20.36M | 16.08M | 21.33M |
| Operating profit | -10.51M | -4.71M | -1.76M | -14.65M | -17.62M | -27.85M | -27.00M | -38.43M |
| Pretax profit | -10.89M | -5.54M | -3.15M | -18.33M | -18.99M | -28.93M | -25.74M | -38.59M |
| Tax | -- | -- | -- | -- | 0 | 36.42K | 1.80K | 19.09K |
| Net profit | -10.89M | -5.54M | -3.15M | -18.33M | -18.99M | -28.97M | -25.74M | -38.61M |
| Basic EPS | -1 | 0 | 0 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.76 | -0.43 | -0.24 | -1.47 | -0.96 | -1.17 | -0.76 | -1.03 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.27M | 3.07M | 2.47M | 8.30M | 4.78M | 5.30M |
| Research & development | 3.85M | 5.20M | 4.42M | 7.87M | 11.17M | 12.81M |
| Operating profit | -7.12M | -8.26M | -6.88M | -16.16M | -15.96M | -18.10M |
| Pretax profit | -6.76M | -8.74M | -6.37M | -16.71M | -12.64M | -14.46M |
| Tax | 2.79K | 5.58K | -623 | 11.34K | 13.91K | 30.38K |
| Net profit | -6.77M | -8.75M | -6.37M | -16.72M | -12.65M | -14.49M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.21 | -0.26 | -0.19 | -0.37 | -0.23 | -0.23 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.82M | 2.02M | 892.64K | 24.00M | 18.59M | 19.80M | 34.44M | 85.10M |
| Cash & ST investments | 604.60K | 885.02K | 117.73K | 23.45M | 18.26M | 19.34M | 33.10M | 80.56M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 2.14M | 2.51M | 1.14M | 24.49M | 19.12M | 20.27M | 34.94M | 86.15M |
| Total current liabilities | 10.53M | 15.82M | 17.68M | 1.78M | 3.06M | 19.37M | 3.10M | 5.63M |
| Short-term debt | 2.78M | 8.95M | 9.86M | 121.41K | 129.82K | 10.45M | 71.86K | 78.45K |
| Long-term debt | -- | -- | -- | 7.27M | 8.80M | -- | -- | -- |
| Total liabilities | 10,531,692.40 | 16,394,702.47 | 18,128,897.55 | 9,152,116.05 | 11,914,395.00 | 19,373,903.00 | 3,103,386.00 | 5,703,915.00 |
| Total equity | -8.40M | -13.88M | -16.99M | 15.34M | 7.21M | 892.33K | 31.84M | 80.45M |
| Retained earnings | -29.39M | -36.13M | -40.15M | -58.18M | -77.28M | -105.50M | -131.00M | -169.58M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 28.61M | 22.83M | 91.40M | 85.10M | 142.13M | 136.80M |
| Cash & ST investments | 27.45M | 19.77M | 88.96M | 80.56M | 138.88M | 133.66M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 29.23M | 23.60M | 92.35M | 86.15M | 145.35M | 139.91M |
| Total current liabilities | 2.20M | 2.62M | 3.81M | 5.63M | 7.36M | 8.55M |
| Short-term debt | 52.77K | 35.07K | 76.14K | 78.45K | 203.51K | 159.88K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 2,199,991.00 | 2,618,381.00 | 3,905,493.00 | 5,703,915.00 | 9,165,681.00 | 10,233,774.00 |
| Total equity | 27.03M | 20.98M | 88.44M | 80.45M | 136.19M | 129.67M |
| Retained earnings | -137.77M | -146.51M | -152.87M | -169.58M | -182.23M | -196.72M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -6.11M | -3.96M | -316.65K | -11.48M | -14.40M | -20.75M | -29.99M | -28.55M |
| Depreciation & amortization | 92.38K | 154.59K | 91.60K | 87.47K | 147.89K | 155.53K | 171.72K | 237.72K |
| Free cash flow | -6.21M | -3.97M | -316.65K | -11.82M | -14.63M | -20.82M | -30.10M | -29.14M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 29.67M | 10.64M | 15.89M | 54.56M | 73.89M |
| Ending cash balance | 604.60K | 885.02K | 117.73K | 16.39M | 18.26M | 19.34M | 33.10M | 80.56M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -6.00M | -8.32M | -4.51M | -9.73M | -10.15M | -13.09M |
| Depreciation & amortization | 46.49K | 55.43K | 62.99K | 72.81K | 90.15K | 134.94K |
| Free cash flow | -6.17M | -8.48M | -4.57M | -9.92M | -10.47M | -13.27M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 73.89M | 0 | 58.63M | -9.27M |
| Ending cash balance | 27.45M | 19.77M | 88.96M | 80.56M | 58.50M | 52.43M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -134.62 | -482.90 | -1,302.55 | -142.87 |
| ROA %i | -286.50 | -236.24 | -171.54 | -140.71 | -78.70 | -143.50 | -92.39 | -63.71 |
| ROIC %i | -- | -- | -- | -- | -80.47 | -187.18 | -358.93 | -147.27 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.17 | 0.13 | 0.05 | 13.49 | 6.08 | 1.02 | 11.10 | 15.12 |
| Quick ratioi | 0.16 | 0.12 | 0.03 | 13.37 | 6.00 | 1.01 | 10.74 | 14.43 |
| Debt / assetsi | 130.38 | 363.38 | 878.42 | 30.61 | 46.99 | 51.57 | 0.21 | 0.18 |
| LT debt / equityi | -- | -- | -- | 46.11 | 113.74 | -- | -- | 0.15 |
| Interest coveragei | -103.33 | -3.95 | -1.13 | -17.02 | -14.06 | -23.72 | -41.65 | -- |
| Revenue CAGR (3Y) %i | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -318.95 | -1,019.28 | -86.59 | -142.87 | -84.74 | -111.03 |
| ROA %i | -79.62 | -119.23 | -57.20 | -63.71 | -50.94 | -62.89 |
| ROIC %i | -208.59 | -575.54 | -88.35 | -147.27 | -84.14 | -111.06 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 13.00 | 8.72 | 23.98 | 15.12 | 19.30 | 16.00 |
| Quick ratioi | 12.59 | 7.60 | 23.38 | 14.43 | 18.95 | 15.71 |
| Debt / assetsi | 0.18 | 0.15 | 0.18 | 0.18 | 1.38 | 1.32 |
| LT debt / equityi | -- | -- | 0.16 | 0.15 | 1.67 | 1.65 |
| Interest coveragei | -92.31 | -49,367.10 | -214,649.38 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 09:55:38 · For reference only, not investment advice and not tailored to your situation.